Ovarian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms (∼ 80%)1; however, other less-common pathologic subtypes must be considered in treatment guidelines. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer discuss epithelial ovarian cancer (including borderline or low malignant potential) and less-common histopathologies, including malignant germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors of the ovary [MMMT]), and sex cord-stromal tumors. The guidelines also discuss fallopian tube and primary peritoneal cancers, which are less-common neoplasms that are managed similarly to epithelial ovarian cancer. However, the less-common histologies of ovarian cancer are managed differently. Information on the less-common ovarian histopathologies are not published in this issue of JNCCN, but can be found online at www.NCCN.org.Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and the country's fifth most common cause of cancer mortality in women. In 2010, an estimated 21,900 new diagnoses and 13,900 deaths will occur from this neoplasm in the United States; fewer than 40% of women with ovarian cancer are cured.2,3 The incidence of ovarian cancer increases with age and is most prevalent in the eighth decade of life, with a rate of 57 per 100,000 women. The median age at diagnosis is 63 years, and 70% of patients present with advanced disease.4Epidemiologic studies have identified risk factors for ovarian cancer. A 30% to 60% decreased risk of cancer is associated...
  • 1.

    Chan JK, Cheung MK, Husain A. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521528.

  • 2.

    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277300.

  • 3.

    Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225249.

  • 4.

    Fleming GF, Ronnett BM, Seidman J. Epithelial ovarian cancer. In: Barakat RR, Markman M, Randall ME, eds. Principles and Practice of Gynecologic Oncology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:763836.

    • Search Google Scholar
    • Export Citation
  • 5.

    Morch LS, Lokkegaard E, Andreasen AH. Hormone therapy and ovarian cancer. JAMA 2009;302:298305.

  • 6.

    Finch A, Beiner M, Lubinski J. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185192.

    • Search Google Scholar
    • Export Citation
  • 7.

    Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:8087.

    • Search Google Scholar
    • Export Citation
  • 8.

    Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170177.

  • 9.

    Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 2009;33:376383.

    • Search Google Scholar
    • Export Citation
  • 10.

    Carlson JW, Miron A, Jarboe EA. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008;26:41604165.

    • Search Google Scholar
    • Export Citation
  • 11.

    Kindelberger DW, Lee Y, Miron A. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161169.

    • Search Google Scholar
    • Export Citation
  • 12.

    Medeiros F, Muto MG, Lee Y. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230236.

    • Search Google Scholar
    • Export Citation
  • 13.

    Semmel DR, Folkins AK, Hirsch MS. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol 2009;22:985988.

    • Search Google Scholar
    • Export Citation
  • 14.

    Goff BA, Mandel LS, Drescher CW. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109:221227.

    • Search Google Scholar
    • Export Citation
  • 15.

    Andersen MR, Goff BA, Lowe KA. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 2008;113:484489.

  • 16.

    Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. J Natl Cancer Inst 2010;24:222229.

    • Search Google Scholar
    • Export Citation
  • 17.

    Menon U, Gentry-Maharaj A, Hallett R. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327340.

    • Search Google Scholar
    • Export Citation
  • 18.

    Partridge E, Kreimer AR, Greenlee RT. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009;113:775782.

    • Search Google Scholar
    • Export Citation
  • 19.

    Valentin L, Jurkovic D, Van Calster B. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 2009;34:345354.

    • Search Google Scholar
    • Export Citation
  • 20.

    Hartge P. Designing early detection programs for ovarian cancer. J Natl Cancer Inst 2010;102:34.

  • 21.

    Horvath G, Jarverud GA, Jarverud S, Horvath I. Human ovarian carcinomas detected by specific odor. Integr Cancer Ther 2008;7:7680.

  • 22.

    Horvath G, Chilo J, Lindblad T. Different volatile signals emitted by human ovarian carcinoma and healthy tissue. Future Oncol 2010;6:10431049.

    • Search Google Scholar
    • Export Citation
  • 23.

    Lu KH, Skates S, Bevers TB. A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA) [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 5003.

    • Search Google Scholar
    • Export Citation
  • 24.

    Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99:447461.

    • Search Google Scholar
    • Export Citation
  • 25.

    Earle CC, Schrag D, Neville BA. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006;98:172180.

    • Search Google Scholar
    • Export Citation
  • 26.

    du Bois A, Quinn M, Thigpen T. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):viii7viii12.

    • Search Google Scholar
    • Export Citation
  • 27.

    Visintin I, Feng Z, Longton G. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:10651072.

  • 28.

    Drapkin R, von Horsten HH, Lin Y. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:21622169.

    • Search Google Scholar
    • Export Citation
  • 29.

    Nolen B, Velikokhatnaya L, Marrangoni A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440445.

    • Search Google Scholar
    • Export Citation
  • 30.

    Anderson GL, McIntosh M, Wu L. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:2638.

    • Search Google Scholar
    • Export Citation
  • 31.

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

  • 32.

    Im SS, Gordon AN, Buttin BM. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:3541.

  • 33.

    ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007;110:201214.

  • 34.

    Dearking AC, Aletti GD, McGree ME. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007;110:841848.

  • 35.

    Timmerman D, Testa AC, Bourne T. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008;31:681690.

    • Search Google Scholar
    • Export Citation
  • 36.

    Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol 2010;194:311321.

    • Search Google Scholar
    • Export Citation
  • 37.

    Vergote I, De Brabanter J, Fyles A. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176182.

    • Search Google Scholar
    • Export Citation
  • 38.

    DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 8th ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

    • Search Google Scholar
    • Export Citation
  • 39.

    Schilder JM, Thompson AM, DePriest PD. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:17.

    • Search Google Scholar
    • Export Citation
  • 40.

    Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:28732883.

  • 41.

    Wright JD, Shah M, Mathew L. Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009;115:41184126.

  • 42.

    Satoh T, Hatae M, Watanabe Y. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 2010;28:17271732.

    • Search Google Scholar
    • Export Citation
  • 43.

    Stier EA, Barakat RR, Curtin JP. Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol 1996;87:737740.

  • 44.

    Eisenhauer EL, Abu-Rustum NR, Sonoda Y. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006;103:10831090.

    • Search Google Scholar
    • Export Citation
  • 45.

    du Bois A, Reuss A, Pujade-Lauraine E. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:12341244.

    • Search Google Scholar
    • Export Citation
  • 46.

    Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;112:265274.

  • 47.

    Aletti GD, Dowdy SC, Gostout BS. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:7785.

    • Search Google Scholar
    • Export Citation
  • 48.

    Eisenhauer EL, Abu-Rustum NR, Sonoda Y. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008;108:276281.

    • Search Google Scholar
    • Export Citation
  • 49.

    Panici PB, Maggioni A, Hacker N. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560566.

    • Search Google Scholar
    • Export Citation
  • 50.

    Aletti GD, Powless C, Bakkum-Gamez J. Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. Gynecol Oncol 2009;114:3236.

    • Search Google Scholar
    • Export Citation
  • 51.

    du Bois A, Reuss A, Harter P. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010;28:17331739.

    • Search Google Scholar
    • Export Citation
  • 52.

    Wimberger P, Lehmann N, Kimmig R. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:6974.

    • Search Google Scholar
    • Export Citation
  • 53.

    Rose PG, Nerenstone S, Brady MF. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:24892497.

  • 54.

    van der Burg ME, van Lent M, Buyse M. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629634.

    • Search Google Scholar
    • Export Citation
  • 55.

    Colombo PE, Mourregot A, Fabbro M. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 2009;35:135143.

    • Search Google Scholar
    • Export Citation
  • 56.

    Steed H, Oza AM, Murphy J. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl 1):4753.

    • Search Google Scholar
    • Export Citation
  • 57.

    Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2009:CD006014.

    • Search Google Scholar
    • Export Citation
  • 58.

    Tiersten AD, Liu PY, Smith HO. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group study S0009. Gynecol Oncol 2009;112:444449.

    • Search Google Scholar
    • Export Citation
  • 59.

    Vandenput I, Van Calster B, Capoen A. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer 2009;101:244249.

    • Search Google Scholar
    • Export Citation
  • 60.

    Vergote I, Trope CG, Amant F. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943953.

  • 61.

    Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.

  • 62.

    Young RC, Walton LA, Ellenberg SS. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:10211027.

    • Search Google Scholar
    • Export Citation
  • 63.

    Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006;24:988994.

    • Search Google Scholar
    • Export Citation
  • 64.

    Marth C, Walker JL, Barakat RR. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007;109:645649.

    • Search Google Scholar
    • Export Citation
  • 65.

    Ozols RF, Bundy BN, Greer BE. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:31943200.

    • Search Google Scholar
    • Export Citation
  • 66.

    Vasey PA, Jayson GC, Gordon A. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:16821691.

    • Search Google Scholar
    • Export Citation
  • 67.

    McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:16.

    • Search Google Scholar
    • Export Citation
  • 68.

    Bell J, Brady MF, Young RC. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432439.

    • Search Google Scholar
    • Export Citation
  • 69.

    Katsumata N, Yasuda M, Takahashi F. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:13311338.

    • Search Google Scholar
    • Export Citation
  • 70.

    Markman M. Management of ovarian cancer. An impressive history of improvement in survival and quality of life. Oncology (Williston Park) 2006;20:347354.

    • Search Google Scholar
    • Export Citation
  • 71.

    Wenzel LB, Huang HQ, Armstrong DK. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:437443.

    • Search Google Scholar
    • Export Citation
  • 72.

    Markman M. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer. Cancer J 2009;15:105109.

  • 73.

    Zeimet AG, Reimer D, Radl AC. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res 2009;29:28032808.

    • Search Google Scholar
    • Export Citation
  • 74.

    Walker JL, Armstrong DK, Huang HQ. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100:2732.

    • Search Google Scholar
    • Export Citation
  • 75.

    Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006;24:45284530.

  • 76.

    Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. J Clin Oncol 2006;24:45314533.

  • 77.

    Ozols RF, Bookman MA, du Bois A. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 2006;103:16.

    • Search Google Scholar
    • Export Citation
  • 78.

    Bookman MA. Dose-dense chemotherapy in advanced ovarian cancer. Lancet 2009;374:13031305.

  • 79.

    Burger RA, Brady MF, Bookman MA. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study [abstract]. J Clin Oncol 2010;28(Suppl 18):Abstract LBA1.

    • Search Google Scholar
    • Export Citation
  • 80.

    Mobus V, Wandt H, Frickhofen N. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007;25:41874193.

    • Search Google Scholar
    • Export Citation
  • 81.

    Papadimitriou C, Dafni U, Anagnostopoulos A. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant 2008;41:547554.

    • Search Google Scholar
    • Export Citation
  • 82.

    Bookman MA, Brady MF, McGuire WP. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009;27:14191425.

    • Search Google Scholar
    • Export Citation
  • 83.

    Markman M, Liu PY, Wilczynski S. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:24602465.

    • Search Google Scholar
    • Export Citation
  • 84.

    Castells MC, Tennant NM, Sloane DE. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574580.

    • Search Google Scholar
    • Export Citation
  • 85.

    Dizon DS, Sabbatini PJ, Aghajanian C. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002;84:378382.

    • Search Google Scholar
    • Export Citation
  • 86.

    Sampson HA, Munoz-Furlong A, Campbell RL. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006;47:373380.

    • Search Google Scholar
    • Export Citation
  • 87.

    Manivannan V, Decker WW, Stead LG. Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis. Int J Emerg Med 2009;2:35.

    • Search Google Scholar
    • Export Citation
  • 88.

    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601609.

  • 89.

    Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424436.

    • Search Google Scholar
    • Export Citation
  • 90.

    Markman M, Zanotti K, Peterson G. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003;21:46114614.

    • Search Google Scholar
    • Export Citation
  • 91.

    Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005;99:393399.

    • Search Google Scholar
    • Export Citation
  • 92.

    Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004;95:370376.

    • Search Google Scholar
    • Export Citation
  • 93.

    Markman M, Hsieh F, Zanotti K. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004;130:2528.

    • Search Google Scholar
    • Export Citation
  • 94.

    Corn BW, Lanciano RM, Boente M. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer 1994;74:29792983.

    • Search Google Scholar
    • Export Citation
  • 95.

    Tinger A, Waldron T, Peluso N. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys 2001;51:12561263.

    • Search Google Scholar
    • Export Citation
  • 96.

    Fulham MJ, Carter J, Baldey A. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009;112:462468.

    • Search Google Scholar
    • Export Citation
  • 97.

    Risum S, Hogdall C, Markova E. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer 2009;19:600604.

    • Search Google Scholar
    • Export Citation
  • 98.

    Allard J, Somers E, Theil R, Moore RG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 5535.

    • Search Google Scholar
    • Export Citation
  • 99.

    Rustin GJ, van der Burg ME. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) [abstract]. J Clin Oncol 2009;27(Suppl 18S):Abstract 1.

    • Search Google Scholar
    • Export Citation
  • 100.

    Miller RE, Rustin GJ. How to follow-up patients with epithelial ovarian cancer. Curr Opin Oncol 2010;22:498502.

  • 101.

    Markman M, Petersen J, Belland A, Burg K. CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial. Oncology 2010;78:12.

    • Search Google Scholar
    • Export Citation
  • 102.

    Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol 2010;7:335339.

  • 103.

    Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010;116:28502853.

    • Search Google Scholar
    • Export Citation
  • 104.

    Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991;68:269271.

    • Search Google Scholar
    • Export Citation
  • 105.

    Van Der Velden J, Gitsch G, Wain GV. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995;5:301305.

  • 106.

    Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205216.

    • Search Google Scholar
    • Export Citation
  • 107.

    Markman M, Blessing J, Rubin SC. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436440.

    • Search Google Scholar
    • Export Citation
  • 108.

    Sharma R, Graham J, Mitchell H. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pretreated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009;100:707712.

    • Search Google Scholar
    • Export Citation
  • 109.

    Markman M, Rothman R, Hakes T. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389393.

    • Search Google Scholar
    • Export Citation
  • 110.

    Fung-Kee-Fung M, Oliver T, Elit L. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007;14:195208.

  • 111.

    Parmar MK, Ledermann JA, Colombo N. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:20992106.

    • Search Google Scholar
    • Export Citation
  • 112.

    Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144153.

    • Search Google Scholar
    • Export Citation
  • 113.

    Strauss HG, Henze A, Teichmann A. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol 2007;104:612616.

    • Search Google Scholar
    • Export Citation
  • 114.

    Kushner DM, Connor JP, Sanchez F. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol 2007;105:358364.

    • Search Google Scholar
    • Export Citation
  • 115.

    Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 2005;15(Suppl 1):1822.

    • Search Google Scholar
    • Export Citation
  • 116.

    Pfisterer J, Plante M, Vergote I. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:46994707.

    • Search Google Scholar
    • Export Citation
  • 117.

    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28:33233329.

    • Search Google Scholar
    • Export Citation
  • 118.

    Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:18.

    • Search Google Scholar
    • Export Citation
  • 119.

    Ferrandina G, Ludovisi M, Lorusso D. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26:890896.

    • Search Google Scholar
    • Export Citation
  • 120.

    Mutch DG, Orlando M, Goss T. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:28112818.

    • Search Google Scholar
    • Export Citation
  • 121.

    Rothenberg ML, Liu PY, Wilczynski S. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol 2004;95:506512.

    • Search Google Scholar
    • Export Citation
  • 122.

    Bajetta E, Di Leo A, Biganzoli L. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996;14:25462551.

    • Search Google Scholar
    • Export Citation
  • 123.

    Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405410.

    • Search Google Scholar
    • Export Citation
  • 124.

    Rose PG, Blessing JA, Ball HG. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:130135.

    • Search Google Scholar
    • Export Citation
  • 125.

    Miller DS, Blessing JA, Krasner CN. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27:26862691.

    • Search Google Scholar
    • Export Citation
  • 126.

    Teneriello MG, Tseng PC, Crozier M. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009;27:14261431.

    • Search Google Scholar
    • Export Citation
  • 127.

    Alberts DS, Jiang C, Liu PY. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer 2004;14:224228.

    • Search Google Scholar
    • Export Citation
  • 128.

    Markman M, Hakes T, Reichman B. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992;10:243248.

    • Search Google Scholar
    • Export Citation
  • 129.

    Bidus MA, Webb JC, Seidman JD. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006;102:57.

    • Search Google Scholar
    • Export Citation
  • 130.

    Wright JD, Hagemann A, Rader JS. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006;107:8389.

    • Search Google Scholar
    • Export Citation
  • 131.

    Burger RA, Sill MW, Monk BJ. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:51655171.

    • Search Google Scholar
    • Export Citation
  • 132.

    Cannistra SA, Matulonis UA, Penson RT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:51805186.

    • Search Google Scholar
    • Export Citation
  • 133.

    Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007;107:118123.

    • Search Google Scholar
    • Export Citation
  • 134.

    Ferrandina G, Ludovisi M, De Vincenzo R. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 2007;18:13481353.

    • Search Google Scholar
    • Export Citation
  • 135.

    Wolf JK, Bodurka DC, Verschraegen C. A phase II trial of oral capecitabine in patients with platinum—and taxane— refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 2006;102:468474.

    • Search Google Scholar
    • Export Citation
  • 136.

    Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther 2006;6:4347.

  • 137.

    Papadimitriou CA, Markaki S, Siapkaras J. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004;66:112117.

    • Search Google Scholar
    • Export Citation
  • 138.

    Bowman A, Gabra H, Langdon SP. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:22332239.

    • Search Google Scholar
    • Export Citation
  • 139.

    del Carmen MG, Fuller AF, Matulonis U. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 2003;91:596602.

    • Search Google Scholar
    • Export Citation
  • 140.

    Ramirez PT, Schmeler KM, Milam MR. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 2008;110:5659.

    • Search Google Scholar
    • Export Citation
  • 141.

    Audeh MW, Carmichael J, Penson RT. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245251.

    • Search Google Scholar
    • Export Citation
  • 142.

    Fong PC, Yap TA, Boss DS. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:25122519.

    • Search Google Scholar
    • Export Citation
  • 143.

    Gelmon KA, Hirte HW, Robidoux A. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 3002.

    • Search Google Scholar
    • Export Citation
  • 144.

    Matsuo K, Eno ML, Im DD. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol 2010;116:6165.

    • Search Google Scholar
    • Export Citation
  • 145.

    Karam AK, Chiang JW, Fung E. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol 2009;114:246252.

    • Search Google Scholar
    • Export Citation
  • 146.

    Cadron I, Leunen K, Van Gorp T. Management of borderline ovarian neoplasms. J Clin Oncol 2007;25:29282937.

  • 147.

    Barakat RR, Benjamin I, Lewis JL Jr. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995;59:390393.

    • Search Google Scholar
    • Export Citation
  • 148.

    Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990;65:578585.

  • 149.

    Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992;47:150158.

    • Search Google Scholar
    • Export Citation
  • 150.

    Barnhill DR, Kurman RJ, Brady MF. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:27522756.

    • Search Google Scholar
    • Export Citation
  • 151.

    Sutton GP, Bundy BN, Omura GA. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991;41:230233.

    • Search Google Scholar
    • Export Citation
  • 152.

    Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 1996;78:278286.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 577 372 22
PDF Downloads 90 63 4
EPUB Downloads 0 0 0